Cardiovascular drugs and analysis of potential risk factors associated with mortality in severe coronavirus disease 2019 patients

AUTOR(ES)

Atabey, Rukiye Derin; Aladağ, Nesim; Şipal, Abdulcebbar; Akbulut, Tayyar; Doğan, Zeki; Özdemir, Mahmut

FONTE

Revista da Associação Médica Brasileira

DATA DE PUBLICAÇÃO

2022

RESUMO

SUMMARY OBJECTIVES: Cardiovascular diseases are also considered to increase the risk of death in COVID-19 patients. However, real-world data concerning the risk factors for death in patients with severe COVID-19 still remain vague. This study aimed to identify the potential risk factors associated with mortality in severe COVID-19 patients. METHODS: All consecutive patients admitted to the intensive care unit (ICU) of our institute for COVID-19 for severe COVID-19 pneumonia from April 1, 2020 to July 20, 2020 were included in the analysis. Patient characteristics, including complete medical history and comorbid diseases, blood test results during admission and on day 7, and clinical characteristics were compared between survivors and nonsurvivors. RESULTS: There was no significant difference between survivors and nonsurvivors regarding age, gender, and preexisting cardiovascular diseases. Moreover, the rate of the medications including angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blockers did not differ between survivors and nonsurvivors. The peak C-reactive protein (CRP), procalcitonin, fibrinogen, and d-dimer levels and the rate for chronic renal failure were significantly higher in nonsurvivors compared with survivors. Intubated patients had a higher risk of death than the others had. CONCLUSIONS: This study failed to demonstrate a significant difference in preexisting cardiovascular diseases and cardiovascular medications between survivors and nonsurvivors who were admitted to ICU for severe COVID-19. Our findings indicate that the presence of chronic renal failure, a high peak ferritin concentration, and the need for invasive mechanical ventilation appear predictive for mortality. We propose that these risk factors should be taken into account in defining the risk status of severe COVID-19 patients admitted to the ICU.

Documentos Relacionados

• Profile of cardiovascular risk factors and mortality in patients with symptomatic peripheral arterial disease
• Hemoglobin value may be decreased in patients with severe coronavirus disease 2019
• Secondary bacterial infections in patients with coronavirus disease 2019-associated pneumonia
• A new biomarker in severe pneumonia associated with coronavirus disease 2019: hypoalbuminemia. A prospective study
• Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?